<DOC>
	<DOCNO>NCT01361126</DOCNO>
	<brief_summary>This study examine safety efficacy Recombinant Coagulation Factor IX Albumin Fusion Protein ( rIX-FP ) control prevention bleed episode subject previously receive factor replacement therapy hemophilia B . The study consist screen period , pharmacokinetic ( PK ) period , follow approximately 5 month treatment period . Subjects receive weekly routine prophylactic therapy on-demand treatment bleed episode . In addition , subject routine factor replacement therapy prior study receive on-demand treatment bleed episode .</brief_summary>
	<brief_title>A Safety Efficacy Study Recombinant Factor IX Patients With Severe Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Male subject , 12 65 year old Severe hemophilia B ( FIX activity â‰¤ 2 % ) Subjects receive FIX product ( plasmaderived and/or recombinant FIX ) &gt; 150 exposure day ( EDs ) No history FIX inhibitor formation , detectable inhibitor Screening family history inhibitor FIX Written inform consent study participation obtain undergo study specific procedure Known hypersensitivity FIX product hamster protein Known congenital acquire coagulation disorder congenital FIX deficiency HIV positive subject CD4 count &lt; 200/mm3 Low platelet count , abnormal kidney function , liver disease Ondemand subject experience less 12 6 nontrauma induce bleed episode require treatment FIX product previous 6 3 month , respectively Planned major surgical intervention study period</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>